← Back to patent-cliff list
Pramipexole/Ondansetron
Tier C — Watch / tradePramipexole/Ondansetron
Chase Therapeutics Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRD2, DRD4, DRD3, 5-HT3
Indications (approved)：Treatment-resistant depression, Major depressive disorder
Regional status
US
Phase II
2018-09-10
EU
Phase II
2026-05-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pramipexole/Ondansetron?
Approved indications include: Treatment-resistant depression, Major depressive disorder.
When does the Pramipexole/Ondansetron patent expire?
No public expiry year is available for Pramipexole/Ondansetron yet; this page updates once verified.
How do I get a quote for Pramipexole/Ondansetron intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08